Dr. Hartmut EHRLICH Vice President Global Research & Development, Baxter BioScience, Wien
CV
| 1978-1985 | Medical School: Justus-Liebig-University, Giessen, Germany |
| 1985-1987 | Department of Hematology-Oncology Indiana University, Indianapolis, Indiana, USA |
| 1988-1990 | Department of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands |
| 1990-1991 | Max-Planck-Gesellschaft, Kerckhoff-Clinic for Cardiology/Cardiovascular Surgery |
| 1991-1995 | Sandoz Pharma (now Novartis Pharma) |
| since 1995 | Baxter Healthcare Corporation |
| since 2006 | Vice President Global Research and Development Baxter BioScience |
Mitgliedschaften
| American Society of Hematology (ASH) | |
| International Society for Thrombosis and Hemostasis (ISTH) | |
| Gesellschaft für Thrombose und Hämostaseforschung (GTH) | |
| Internatonal Society for Infectious Diseases (ISID) |
Publikationen
| Ehrlich, H. J. et al.: Recombinant human protein C derivatives: Altered response to calcium resulting in enhanced activation by thrombin. EMBO J. 9: 2367 2373, 1990 | |
| Ehrlich, H. J. et al.: Thrombin neutralizes plasminogen activator inhibitor 1 (PAI 1) that is complexed with vitronectin in the endothelial cell matrix. J. Cell Biol. 115: 1773-1781, 1991 | |
| Ehrlich, H. J. et al.: Safety and Immunogenicity of the Modified Adult Tick-Borne Encephalitis Vaccine FSME-IMMUN: Results of Two Large Phase 3 Clinical Studies. Vaccines 24: 5256-5263, 2006 | |
| Ehrlich H. J. et al.: A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture. N Engl J Med; 358: 2573-84, 2008 |
Auszeichnungen
| Doctoral Thesis: Summa cum laude, 1986 | |
| ECFMG Certificate (US Medical Exam), 1986 | |
| Indiana University School of Medicine, Fellow, 1987 | |
| Symposium Meningitis in Children, 12. ICID (Lisbon), Chairman and Speaker, 2006 |
